Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Neusoft Medical introduces NeuViz 64 multi-slice CT scanner

Neusoft Medical Systems Co., Ltd., a wholly-owned subsidiary of Neusoft Corporation, today announced its introduction of NeuViz 64 multi-slice CT scanner into the global market. This device, developed independently by Neusoft Medical, debuted at the 67th China International Medical Equipment Fair (CMEF) Spring 2012.

14 May 2012

Event addresses FDA's recent draft guidelines for development of biosimilar products

Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (Alliance) outlined five areas of concern that the U.S. Food and Drug Administration (FDA) should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA's May 11th public hearing. The event addressed the FDA's recent draft guidelines for the development of biosimilar products.

14 May 2012

FDA ADAC recommends approval of Quad for HIV-1 infection

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naïve adults.

14 May 2012

3SBio first quarter total net revenues increase 24.5% to RMB147.2M

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2012.

14 May 2012

'Packing problem' could have a solution for cancer treatment

A hidden facet of a math problem that goes back to Sanskrit scrolls has just been exposed by nanotechnology researchers at the University of Michigan and the University of Connecticut.

11 May 2012

Osiris Therapeutics first quarter total revenues decrease to $4.6M

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and commercializing products to treat medical conditions in inflammatory, cardiovascular, orthopedic, and wound healing markets, announced today its results for the first quarter ended March 31, 2012.

11 May 2012

Pacira first quarter total revenues increase to $7.8 million

Pacira Pharmaceuticals, Inc. today announced consolidated financial results for the quarter ended March 31, 2012 and reviewed recent accomplishments, including the commercial launch in the United States of EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain and the successful completion of an equity financing.

9 May 2012

BioDiem announces new vaccine research collaboration with French-based VIVALIS

Australian vaccine development company BioDiem Ltd (ASX: BDM) today announced that it has begun a research collaboration with France-based VIVALIS (Euronext code: VLS), a biopharmaceutical company with expertise in vaccine production technologies.

9 May 2012

Lannett third quarter net sales increase 19% to $30.7 million

Lannett Company, Inc. today reported financial results for the fiscal 2012 third quarter and nine months ended March 31, 2012.

9 May 2012

GenMark Diagnostics first quarter revenues increase to $2.2M

GenMark Diagnostics, Inc. today reported financial results for the first quarter ended March 31, 2012.

9 May 2012

Medifast first quarter net revenue increases 20% to $88.9 million

Medifast, Inc.a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs, today reported financial results for the first quarter ended March 31, 2012.

9 May 2012

Mindray first quarter net revenues increase 21.1% to $219.0 million

Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the first quarter ended March 31, 2012.

From Mindray 8 May 2012

Halozyme first quarter net loss increases to $15.1 million

Halozyme Therapeutics, Inc. today reported financial results for the quarter ended March 31, 2012.

8 May 2012

Claraview reports successful deployment of Enterprise Data Integrity solution for Affinity Health Plan

Claraview, a division of Teradata, a strategy and technology consultancy focused exclusively on business intelligence (BI) and analytic solutions, announced today the successful deployment of the Enterprise Data Integrity (EDI) solution for Affinity Health Plan.

7 May 2012

ADVENTRX first quarter net loss increases to $4.2M

ADVENTRX Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2012.

7 May 2012

Pro-Dex third quarter sales decrease 34% to $4.5 million

PRO-DEX, INC. today announced financial results for its fiscal third quarter and nine months ended March 31, 2012.

5 May 2012

Breckenridge finalizes agreement with Huahai to market Nevirapine Tablets

Breckenridge Pharmaceutical, Inc. announced today that it has finalized its agreement with Zhejiang Huahai Pharmaceuticals Co., Ltd. (Huahai) to market Nevirapine Tablets. Nevirapine 200mg Tablets are AB rated to Viramune a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS, which is marketed by Boehringer Ingelheim.

5 May 2012

Researchers develop new kind of hip implant

Hip replacement is one of the most frequent operations carried out in Germany. Each year, doctors implant some 200,000 artificial hip joints. Often the artificial hips need to be replaced just ten years later. In the future, a new implant currently being developed using high technology materials could help prevent premature revision surgeries.

5 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Affymetrix total revenue decreases to $65.2 million

Affymetrix, Inc., today reported its operating results for the first quarter of 2012. Total revenue for the quarter was $65.2 million, as compared to total revenue of $73.7 million for the same period of 2011.

4 May 2012